LifeMD
| Company type | Public |
|---|---|
| Industry | Telehealth, virtual medical consultations |
| Predecessor | ImmuDyne, Inc., Conversion Labs, Inc. |
| Founded | 1994 |
| Headquarters | United States |
Key people | Justin Schreiber (CEO) |
| Products | Virtual medical consultations, prescription services |
LifeMD, Inc. is a U.S.-based telehealth company publicly traded on the stock market, delivering virtual medical consultations and prescription services through licensed doctors and nurse practitioners to its subscribers.
History
Originally established in 1994 under the name ImmuDyne, Inc., the firm went public in 2001. In 2018, it underwent a rebranding to Conversion Labs, Inc., with Justin Schreiber stepping in as CEO. The company adopted the LifeMD name in 2020 and began trading under the ticker symbol LFMD.
During the first quarter of 2025, LifeMD announced a revenue growth of 49% compared to the previous year, reaching $65.7 million.
Services
In September 2022, LifeMD welcomed former Louisiana governor Bobby Jindal to its board of directors.
By June 2023, LifeMD introduced a weight management initiative prescribing GLP-1 medications after virtual consultations with healthcare providers. This effort included a pilot program with Medifast, which evolved into a formal partnership involving customer referrals and a $20 million investment from Medifast into LifeMD.
Starting in 2024, LifeMD began accepting private health insurance coverage for its telehealth services.
In March 2025, LifeMD secured a deal to provide Eli Lilly’s weight-loss medication Zepbound at reduced prices for patients paying out-of-pocket through LillyDirect’s pharmacy network. That same year, shares of LifeMD rose sharply following a collaboration with Novo Nordisk to offer Wegovy at discounted rates on its platform.
Expanding its portfolio in April 2025, LifeMD acquired Optimal Human Health MD, strengthening its capabilities in women’s health areas such as hormone therapy, metabolic health, and bone density management.